Dexcom survey shows healthcare providers opt for CGM tech over new medications in Type 2 diabetes

Healthcare Providers Favor CGM Technology Over Medications

Dexcom's multi-region report, unveiled at ATTD 2025, surveyed over 2,500 people across Europe and the Middle East. The key findings reveal:

52% of healthcare professionals ranked access to CGM technology and education as having greater potential to help people with Type 2 diabetes manage their condition over the next 10 years, compared to 38% who favored better or more effective medications1 7.
96% of healthcare providers agreed that CGM should be the standard of care for patients using multiple daily insulin injections8.
93% of CGM users reported a positive impact, significantly exceeding pre-use expectations of 77%8.

Benefits of CGM Technology

The survey highlights several advantages of CGM technology:

Provides continuous data stream of glucose values and optional alerts for abnormal glucose levels16.
Reduces therapeutic inertia and empowers patients to make healthier choices16.
Improves glycemic control and increases time in range for patients16.
Serves as an educational and motivational tool for lifestyle modifications12.

Implications for Type 2 Diabetes Care

The findings suggest a shift in diabetes management strategies:

Healthcare providers are recognizing the value of real-time data and patient engagement offered by CGM technology.
There is a growing emphasis on technology-enabled self-management and education over solely medication-based approaches.
CGM use could potentially lead to better long-term health outcomes and reduced healthcare costs for Type 2 diabetes patients7.

Call to Action

The report serves as a call to action for policymakers, highlighting:

The need for greater investment in CGM technology as a core component of Type 2 diabetes management7.
The importance of enhancing CGM accessibility to tackle the Type 2 diabetes crisis7.
The potential for CGM to empower patients, improve quality of life, and reduce complications7.

This survey demonstrates a significant shift in healthcare provider preferences towards CGM technology for managing Type 2 diabetes, suggesting a future where technology plays an increasingly central role in diabetes care.